Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study

ECCO'20 Vienna

Year: 2020
Authors:

T. Paupard1, F. Gonzalez2, L. Siproudhis3, L. Peyrin-Biroulet4, Thierry Paupard

1Centre Hospitalier de Dunkerque, Gastroenterology, Dunkerque, France, 2Cabinet d’Hépato Gastroentérologie, Gastroenterology, Nîmes, France, 3CHU Pontchaillou, Gastroenterology, Rennes, France, 4CHU Brabois, Gastroenterology, Vandœuvre-lès-Nancy, France

P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey

ECCO'20 Vienna

Year: 2020
Authors:

S. Volmar1, S. Wildt2,3, L.K. Munck2,3

1Section of Gastroenterology, Department of Internal Medicine, Zealand University Hospital Køge, DK-4600, Køge, Denmark, 2Section of Gastroenterology, Department of Internal Medicine, Zealand University Hospital Køge, DK-4600 Køge, Denmark, 3Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, A. Kavanaugh2, R. Westhovens3, K. Winthrop4, S. Lee5, J. Greer6, A. DeZure6, D. An7, L. Ye7, J. Sundy6, L. Meuleners8, R. Alten9, M. Genovese10

1Galapagos NV, Clinical Development, Mechelen, Belgium, 2Department of Rheumatology, University of California, San Diego, CA, USA, 3Department of Rheumatology, University UZ Leuven, Leuven, Belgium, 4Department of Rheumatology, Oregon Health and Science University, Portland, OR, USA, 5Gilead Sciences Inc., Department of Medical Affairs, Foster City, CA, USA, 6Department of Clinical Research, Gilead Sciences Inc., Foster City, CA, USA, 7Department of Biostatistics, Gilead Sciences Inc., Foster City, CA, USA, 8Department of Biostatistics, Galapagos NV, Mechelen, Belgium, 9Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, Berlin, Germany, 10Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA

P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

F. Nordin1, B. Shadbolt2, K. Subramaniam1,3

1Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia, 2Health Analytics Research Centre, ACT Health, Canberra, Australia, 3Australian National University Medical School, Australian National University, Canberra, Australia

P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

D. Tassone1, N. Ding2

1St Vincent’s Clinical School, University of Melbourne, Fitzroy, Australia, 2Department of Gastroenterology, St Vincent’s Hospital Melbourne, Fitzroy, Australia

P528 Response to biologic therapy in operated Crohn’s disease patients

ECCO'20 Vienna

Year: 2020
Authors:

A.C. Georgieva, A. Atanassova, M. Mirchev

Clinic of Gastroenterology, University Hospital St. Marina, Medical University, Varna, Bulgaria

P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre

ECCO'20 Vienna

Year: 2020
Authors:

M. Sonnino, A. Ocholi, A. ElZein, E. Saliakellis, L. Pensabene, O. Borrelli, F. Kiparissi

Department of Gastroenterology, Great Ormond Street Hospital, London, UK

P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

I. Diakite1, B. Schultz2, J. Carter1, S. Snedecor1, R. Turpin3

1Department of Gastroenterology, Pharmerit International, Bethesda, USA, 2Department of Gastroenterology, Takeda Pharmaceuticals, Deerfield, USA, 3Department of Gastroenterology, Takeda Pharmaceuticals U.S.A. Inc., Lake Zurich, USA

P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service

ECCO'20 Vienna

Year: 2020
Authors:

C. Watters, W. Lloyd, M. Porteous, M. Mohamed, S. Kari, E. Nelson, R. Saravanan

Department of Gastroenterology, Silk House, Macclesfield District General Hospital, Macclesfield, UK

P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

C. EMONT1, C. Gay2, A.L. Parmentier3, S. Koch4, S. Ambregna5, G. Claudé5, P. Sage5, P. Zhong4, C. Briot5, L. Vuitton4

1Department of Gastroenterology, Besançon University Hospital, Hospital of Haute-Saone, Besançon, Vesoul, France, 2Department of Gastroenterology, Lyon University Hospital, Lyon, France, 3Center of Clinical Methodology, Besançon University Hospital, Besançon, France, 4Department of Gastroenterology, Besançon University Hospital, Besançon, France, 5Department of Gastroenterology, Hospital of Haute-Saone, Vesoul, France

P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Angriman, G. Bordignon, E. Sciuto, O. Zini, N. Bortoli, M. Gruppo, R. Bardini, C. Ruffolo, M. Scarpa

Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy

P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

J. Popov1,2, E. Hartung1, L. Hill1,3, U. Chauhan4, N. Pai1,5, McMaster Paediatric FMT Research Program

1Division of Gastroenterology and Nutrition, Department of Paediatrics, McMaster University, Hamilton, Canada, 2College of Medicine and Health, University College Cork, Cork, Ireland, 3Department of Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South Africa, 4Division of Gastroenterology and Hepatology, Department of Medicine, McMaster University, Hamilton, Canada, 5Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada

P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)

ECCO'20 Vienna

Year: 2020
Authors:

X. Roblin1, A. Serone2, O.K. Yoon3, L. Zhuo3, E. Grant4, J. Woo5, J. Liu3, R. Galien6, G. D’Haens7

1Department of Gastroenterology, University Hospital of Saint Etienne, Saint-Priest-en-Jarez, France, 2Clinical Research, Gilead Sciences Inc., Foster City, USA, 3Department of Bioinformatics, Gilead Sciences Inc., Foster City, USA, 4Clinical Development, Gilead Sciences Inc., Foster City, USA, 5Biomarker Sciences, Gilead Sciences Inc., Foster City, USA, 6Developmental Liaison, Galapagos SASU, Romainville, France, 7Inflammatory Bowel Disease Centre, Amsterdam University Medical Centers, Amsterdam, The Netherlands

P536 Early prediction of intravenous corticosteroid therapy failure in moderate–severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Croft1, A. Lord2, G. Radford-Smith1

1Department of Gastroenterology and Hepatology, Royal Brisbane and Women’s Hospital, Brisbane, Australia, 2QIMR-Berghofer Medical Research Institute, Gut Health Group, Brisbane, Australia

P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry

ECCO'20 Vienna

Year: 2020
Authors:

M.I. Iborra Colomino1, B. Beltrán1, A. Fernández-Clotet2, E. Iglesias Flores3, P. Navarro4, M. Rivero5, A. Gutiérrez6, M. Sierra-Ausin7, F. Mesonero8, R. Ferreiro-Iglesias9, J. Hinojosa10, X. Calvet11, B. Sicilia12, C. González-Muñoza13, B. Antolín14, M. González Vivo15, A.Y. Carbajo16, S. García17, A. Martín-Cardona18, G. Surís Marín19, M.D. Martín-Arranz20, R. De Francisco21, F. Cañete22, T. Carlos23, F. Gomollón24, R. Lorente25, I. Rodríguez-Lago26, A. Forés-Bosch27, E. Bernardos28, L. Ramos29, P. Delgado30, A. Hernández31, M. Van Domselaar32, D. Hervás33, E. Domènech34, P. Nos1

1Department of Gastroenterology, Hospital Universitario y Politécnico La Fe, Valencia, Spain, 2Department of Gastroenterology, Hospital Clínic Barcelona, Barcelona, Spain, 3Department of Gastroenterology, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain, 4Department of Gastroenterology, Hospital Clínico Universitario de Valencia, Valencia, Spain, 5Department of Gastroenterology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Department of Gastroenterology, Hospital General de Alicante, Alicante, Spain, 7Department of Gastroenterology, Complejo Asistencial Universitario de León, León, Spain, 8Department of Gastroenterology, Hospital Ramón y Cajal Madrid, Madrid, Spain, 9Department of Gastroenterology, Hospital Universitario de Santiago, Santiago de Compostela, Spain, 10Department of Gastroenterology, Hospital de Manises, Valencia, Spain, 11Department of Gastroenterology, Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Spain, 12Department of Gastroenterology, Hospital Universitario de Burgos, Burgos, Spain, 13Department of Gastroenterology, Hospital Santa Creu i Sant Pau, Barcelona, Spain, 14Department of Gastroenterology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 1561712@parcdesalutmar.cat, Hospital Parc de Salut Mar, Barcelona, Spain, 16Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain, 17Department of Gastroenterology, Hospital Miguel Servet, Zaragoza, Spain, 18Department of Gastroenterology, Hospital Mutua de Terrassa, Terrassa, Spain, 19Department of Gastroenterology, Hospital de Bellvitge, Barcelona, Spain, 20Department of Gastroenterology, Hospital Universitario La Paz, Madrid, Spain, 21Department of Gastroenterology, Hospital Central de Oviedo, Oviedo, Spain, 22Department of Gastroenterology, Hospital Germans Trias i Pujol, Barcelona, Spain, 23Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain, 24Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 25Department of Gastroenterology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 26Department of Gastroenterology, Hospital Universitario de Galdakao, Galdakao, Spain, 27Department of Gastroenterology, Hospital General de Castellón, Castellón, Spain, 28Department of Gastroenterology, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, 29Department of Gastroenterology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 30Department of Gastroenterology, Hospital General de Granollers, Granollers, Spain, 31Department of Gastroenterology, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, 32Department of Gastroenterology, Hospital Universitario de Torrejón, Madrid, Spain, 33Department of Biostatistics, Hospital Universitario y Politécnico La Fe, Valencia, Spain, 34Department of Gastroenterology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain

P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab

ECCO'20 Vienna

Year: 2020
Authors:

A. Geldhof1, S. Volger2, C.B. Lin2, C. O’Brien2, I. Tikhonov2

1Department of Medical Affairs, Janssen Biologics B.V., Leiden, The Netherlands, 2Department of Immunology, Janssen Research and Development, LLC, Spring House, USA

P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme

ECCO'20 Vienna

Year: 2020
Authors:

G.R. Lichtenstein1, B. Bressler2, S. Vermeire3, C. Francisconi4, N. Lawendy5, H. Shi5, L. Salese5, D. Judd5, E.V. Loftus Jr6

1Division of Gastroenterology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA, 2Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Department of Gastroenterology, University Hospitals - Leuven, Leuven, Belgium, 4Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, Brazil, 5Pfizer Inc., Collegeville, Pennsylvania, USA, 6Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects

ECCO'20 Vienna

Year: 2020
Authors:

B. Levesque1, K. Taylor Meadows2, A. Buch3, M. Flynn4, K. Peters5, A. Olson1, J. Shen1, D. Slee6, C. Van Biene7, R. Aranda1, N. Vande Casteele8, G. Opiteck1

1Clinical Development, Gossamer Bio Inc., San Diego, USA, 2Department of Biology, Gossamer Bio Inc., San Diego, USA, 3Department of Clinical Pharmacology and Pharmacokinetics, Aerpio Pharmaceuticals Inc., Cinncinati, USA, 4Department of Project Management, Aerpio Pharmaceuticals Inc., Cincinnati, USA, 5Department of Research and Development, Aerpio Pharmaceuticals Inc., Cincinnati, USA, 6Department of Research and Development, Gossamer Bio Inc., San Diego, USA, 7Department of Biometrics, Gossamer Bio Inc., San Diego, USA, 8Department of Precision Medicine, Robarts Clinical Trials, San Diego, USA

P541 Are we addressing the top ten research priorities in IBD?

ECCO'20 Vienna

Year: 2020
Authors:

J. Geldof1, J.F. LeBlanc1, L. Lucaciu2, J.P. Segal1, C.W. Lees2, A. Hart1

1IBD Unit, St Mark’s Hospital Academic Institute, London, UK, 2Gastrointestinal Unit, Western General Hospital, Edinburgh, UK

P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

W. Kantasiripitak1, B. Verstockt2,3, T. Lobatón2,3,4, D. Thomas1, A. Gils1, S. Vermeire2,3, M. Ferrante2,3, E. Dreesen1

1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 3Department of Chronic Diseases Metabolism and Ageing, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium